Temporal trends in the use of adjuvant systemic therapy in breast cancer – a population based study in Sweden 1976–2005

References

• Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 2005;365:1687–717.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:1–15.
   PubMed Web of Science ®Google Scholar
• Early Breast Cancer Trialists’ Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. 133 randomised trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:71–85.
   PubMed Web of Science ®Google Scholar
• Nystrom L, Rutqvist LE, Wall S, Lindgren A, Lindqvist M, Ryden S, et al. Breast cancer screening with mammography: Overview of Swedish randomised trials. Lancet 1993; 341: 973–8
   PubMed Web of Science ®Google Scholar
• Berry DA, Cronin KA, Plevritis SK, Fryback DG, Clarke L, Zelen M, et al. Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 2005; 353: 1784–92
   PubMed Web of Science ®Google Scholar
• Vervoort MM, Draisma G, Fracheboud J, van de Poll-Franse LV, de Koning HJ. Trends in the usage of adjuvant systemic therapy for breast cancer in the Netherlands and its effect on mortality. Br J Cancer 2004; 91: 242–7
   PubMed Web of Science ®Google Scholar
• Sarkeala T, Heinavaara S, Anttila A. Organised mammography screening reduces breast cancer mortality: A cohort study from Finland. Int J Cancer 2008; 122: 614–9
   PubMedGoogle Scholar
• Jonsson H, Tornberg S, Nystrom L, Lenner P. Service screening with mammography in Sweden–evaluation of effects of screening on breast cancer mortality in age group 40–49 years. Acta Oncol 2000; 39: 617–23
   PubMedGoogle Scholar
• Duffy SW, Tabar L, Chen HH, Holmqvist M, Yen MF, Abdsalah S, et al. The impact of organized mammography service screening on breast carcinoma mortality in seven Swedish counties. Cancer 2002; 95: 458–69
   PubMed Web of Science ®Google Scholar
• Swedish Organised Service Screening Evaluation Group. Reduction in breast cancer mortality from organized service screening with mammography: 1. Further confirmation with extended data. Cancer Epidemiol Biomarkers Prev 2006;15:45–51.
   PubMedGoogle Scholar
• Swedish Organised Service Screening Evaluation Group. Reduction in breast cancer mortality from the organised service screening with mammography: 2. Validation with alternative analytic methods. Cancer Epidemiol Biomarkers Prev 2006;15:52–6.
   PubMedGoogle Scholar
• Tataru D, Robinson D, Moller H, Davies E. Trends in the treatment of breast cancer in Southeast England following the introduction of national guidelines. J Public Health (Oxf) 2006; 28: 215–7
   PubMedGoogle Scholar
• Mariotto A, Feuer EJ, Harlan LC, Wun LM, Johnson KA, Abrams J. Trends in use of adjuvant multi-agent chemotherapy and tamoxifen for breast cancer in the United States: 1975–1999. J Natl Cancer Inst 2002; 94: 1626–34
   PubMedGoogle Scholar
• Centre of Epidemiology. Cancer Incidence in Sweden 2006. National Board of Health and Welfare, Stockholm 2007;
   Google Scholar
• Mattsson B, Wallgren A. Completeness of the Swedish Cancer Register. Non-notified cancer cases recorded on death certificates in 1978. Acta Radiol Oncol 1984; 23: 305–13
   PubMed Web of Science ®Google Scholar
• Rutqvist LE, Cedermark B, Glas U, Johansson H, Nordenskjold B, Skoog L, et al. The Stockholm trial on adjuvant tamoxifen in early breast cancer. Correlation between estrogen receptor level and treatment effect. Breast Cancer Res Treat 1987; 10: 255–66
   PubMed Web of Science ®Google Scholar
• Rutqvist LE, Cedermark B, Glas U, Johansson H, Rotstein S, Skoog L, et al. Randomized trial of adjuvant tamoxifen combined with postoperative radiation therapy or adjuvant chemotherapy in postmenopausal breast cancer. Cancer 1990; 66: 89–96
   PubMed Web of Science ®Google Scholar
• Fisher B, Carbone P, Economou SG, Frelick R, Glass A, Lerner H, et al. 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med 1975; 292: 117–22
   PubMed Web of Science ®Google Scholar
• Bonadonna G, Brusamolino E, Valagussa P, Rossi A, Brugnatelli L, Brambilla C, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976; 294: 405–10
   PubMed Web of Science ®Google Scholar
• Baum M, Brinkley DM, Dossett JA, McPherson K, Patterson JS, Rubens RD, et al. Improved survival among patients treated with adjuvant tamoxifen after mastectomy for early breast cancer. Lancet 1983; 2: 450
   PubMed Web of Science ®Google Scholar
• Ribeiro G, Palmer MK. Adjuvant tamoxifen for operable carcinoma of the breast: report of clinical trial by the Christie Hospital and Holt Radium Institute. Br Med J (Clin Res Ed) 1983; 286: 827–30
   PubMed Web of Science ®Google Scholar
• NIH/NCI. Adjuvant chemotherapy for breast cancer. NIH Concensus Statement 1985;5:1–19.
   Google Scholar
• Thuerlimann B, Koeberle D, Senn HJ. Guidelines for the adjuvant treatment of postmenopausal women with endocrine-responsive breast cancer: Past, present and future recommendations. Eur J Cancer 2007; 43: 46–52
   PubMedGoogle Scholar
• Swedish Organised Service Screening Evaluation Group. Effect of mammographic service screening on stage at presentation of breast cancers in Sweden. Cancer 2007;109:2205–12.
   PubMed Web of Science ®Google Scholar